4-[(2,6-Dimethylphenyl)carbamoyl]butanoic acid | 201137-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(2,6-Dimethylphenyl)carbamoyl]butanoic acid
• 英文别名: 5-(2,6-dimethylanilino)-5-oxopentanoic acid
• CAS: 201137-73-7
• 化学式: C₁₃H₁₇NO₃
• mdl: MFCD00029865
• 分子量: 235.28
• InChiKey: KKGRORPLWTWVBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1810972A1

  公开（公告）日：2007-07-25

  The present invention relates to a compound that has p38 MAP kinase inhibitory activity useful as drug medicine, represented by the general formula (I) : wherein all the symbols are as defined in the description, or itssalt, N-oxide or solvate, or a prodrug thereof. Further, there are provided a process for producing the same and usage thereof. The compound of the general formula (I) has a p38 MAP kinase inhibory activity and is useful for the prevention and/or treatment of diseases in which an abnormal production of cytokine, such as inflammatory cytokine or chemokine, or an over-reaction thereto would be instrumental in the cause and aggravation of pathologic condition thereof, namely, cytokine-mediated diseases, for example, inflammatory diseases, respiratory diseases, circulatory diseases, central nervous diseases, etc.

  本发明涉及一种具有 p38 MAP 激酶抑制活性、可用作药物的化合物，由通式 (I) 表示： 其中所有符号如描述中所定义，或其盐、N-氧化物或溶解物，或其原药。此外，还提供了相同物质的生产工艺及其用途。 通式（I）化合物具有 p38 MAP 激酶抑制活性，可用于预防和/或治疗细胞因子（如炎性细胞因子或趋化因子）的异常产生或其过度反应将有助于引起和加重病理状况的疾病，即细胞因子介导的疾病，例如炎症性疾病、呼吸系统疾病、循环系统疾病、中枢神经疾病等。
• Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
  申请人：Mackerell Alexander

  公开号：US20070099970A1

  公开（公告）日：2007-05-03

  Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.
• Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
  申请人：Mackerell Alexander

  公开号：US20070196395A1

  公开（公告）日：2007-08-23

  Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.
• [EN] IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE PY+3 BINDING SITE OF TYROSENE KINASE P56 LCK SH2 DOMAIN<br/>[FR] COMPOSES IMMUNOMODULATEURS QUI CIBLENT ET INHIBENT LE SITE DE LIAISON PY+3 DU DOMAINE SH2 DE LA TYROSINE KINASE P56 LCK
  申请人：UNIV MARYLAND

  公开号：WO2008024759A2

  公开（公告）日：2008-02-28

  [EN] Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.
  [FR] L'invention concerne des composés non peptidiques de faible poids moléculaire qui bloquent les interactions dépendantes du domaine SH2 de la Lck. Lesdits inhibiteurs omettent la phosphotyrosine (pY) ou des fractions associées.